Why Kureha’s Kremezin capsules quietly matter in chronic kidney care

Kureha’s Kremezin capsules turn an unassuming black oral adsorbent into a long-term companion for patients with chronic kidney disease in Japan. What the therapy can and cannot do in daily use - and where the company stands on the stock market.

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 23:10. Details in the imprint.

With Kremezin capsules, Kureha brings a small black pill into everyday life that is meant to slow down a big disease - chronic kidney failure. Patients swallow the granular adsorbent day after day, often for years, hoping to postpone dialysis a little longer.

What Kremezin actually is

Kremezin is an oral adsorbent made of spherical carbon granules that binds uremic toxins in the gut before they reach the bloodstream and burden the kidneys. According to Kureha’s product information, it is indicated to delay progression of chronic kidney disease in predialysis patients in Japan. Kureha’s official Kremezin page

Patients do not see a futuristic device, just dark granules inside hard capsules. The active carbon feels slightly sandy when a capsule opens, the smell is neutral. The promise is biochemical rather than sensory - less accumulation of protein-bound toxins that kidneys with reduced function cannot clear efficiently.

How the therapy is used in practice

In Japanese routine care, Kremezin is typically prescribed to adults with chronic kidney disease stages 3 to 5 who are not yet on dialysis, often alongside strict blood pressure and diabetes control. Doctors usually prescribe multiple capsules per day, which can feel like a small ritual around meals.

The dosing burden is one of the therapy’s downsides. Several capsules three times a day, over months and years, demand discipline from patients who already juggle blood pressure tablets, phosphate binders and diet rules. Yet many accept it in the hope of gaining more dialysis-free years.

What studies say about its effect

Clinical data from Japan suggest that Kremezin can slow the rise of serum creatinine and postpone the need for dialysis in some patients compared with conventional therapy alone, especially when started early in chronic kidney disease. A peer-reviewed overview of oral carbon adsorbents

The effect is not dramatic like a new heart valve, more like a brake that takes some speed out of an inevitable downhill run. For nephrologists, that still matters - each year without dialysis means fewer hospital visits, more flexibility and usually better perceived quality of life for patients.

Strengths, limits, side effects

One strength of Kremezin is that it works in the gut, not directly in the bloodstream. That keeps systemic drug interactions limited and allows use in many multimorbid elderly patients. However, gastrointestinal side effects such as constipation, fullness and nausea are common in practice.

Some patients complain about a feeling of heaviness in the stomach and the sheer number of daily capsules. Doctors must also monitor fluid balance and nutrition, because a strict diet combined with gut-acting drugs can unintentionally reduce calorie and protein intake in fragile patients.

Where Kremezin is available

Kremezin is primarily marketed in Japan, where Kureha has built its reputation in the nephrology community over decades. The product also reached some other Asian markets through partnerships, but it has never become a global standard therapy in Europe or the United States. Kureha’s pharmaceutical business overview

For European patients, the name may sound exotic; in Japanese dialysis centers it is part of everyday vocabulary. That focus on the home market also means that Kureha tailors packaging, dosage strengths and patient information primarily to local practice patterns and reimbursement rules.

The business role inside Kureha

Economically, Kremezin sits in Kureha’s pharmaceuticals segment alongside other specialty drugs. Kureha reports that pharmaceuticals account for a smaller share of sales than advanced materials and specialty chemicals, but enjoy relatively stable demand and margins thanks to chronic indications like kidney disease. Recent Kureha annual report

The product is not a blockbuster on the scale of global diabetes drugs, yet for a mid-sized Japanese group it is strategically valuable. It gives Kureha a recurring revenue stream that is less exposed to industrial cycles than engineering plastics or packaging materials.

Stock context in one sentence

Kureha Corp (ISIN JP3313200001) is listed on the Tokyo Stock Exchange, and Kremezin contributes to the steadier pharmaceutical share of its diversified earnings mix.

Key facts on Kremezin at a glance

• Product: Kremezin capsules (oral adsorbent)
• Manufacturer: Kureha Corp
• Category: Software/Service/Subscription (pharmaceutical therapy service in chronic care)
• Launch: Initially approved in Japan in the 1990s, with long-standing use in predialysis chronic kidney disease
• RRP / Price: Reimbursed prescription drug in Japan, price set via the national health insurance system rather than a single visible retail price
• Availability: Primarily Japan, with selected presence in other Asian markets through local partners; not broadly available in Germany
• Target group: Adult patients with chronic kidney disease stages 3-5 who have not yet started dialysis
• Highlight / USP: Oral spherical carbon adsorbent aiming to slow kidney function decline by binding uremic toxins in the gastrointestinal tract

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.